Attached files
| file | filename |
|---|---|
| 8-K - Huifeng Bio-Pharmaceutical Technology, Inc. | v228777_8k.htm |
Exhibit 16.1
|
July 15, 2011
Our Ref: H587/adr/hk/ic/u11
PRIVATE AND CONFIDENTIAL
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
|
 |
Ladies and Gentlemen:
We were previously engaged as principal accountants to audit the consolidated financial statements of Huifeng Bio-Pharmaceutical Technology, Inc. as of and for the year ended December 31, 2010. On April 15, 2011, we ceased to be Huifeng Bio-Pharmaceutical Technology, Inc.’s auditors. We have read Huifeng Bio-Pharmaceutical Technology, Inc.’s statements included under Item 4.01 of its Form 8-K dated July 15, 2011. We are not in a position to agree or disagree with Huifeng Bio-Pharmaceutical Technology, Inc.’s statements as presented in the first paragraph. We agree with statements in subsequent paragraphs.
Yours faithfully,
/s/ Baker Tilly Hong Kong Limited
Baker Tilly Hong Kong Limited
cc: Huifeng Bio-Pharmaceutical Technology Inc.
